Greg Yap

Greg Yap stands as a distinguished Partner at Menlo Ventures, a leading venture capital firm renowned for backing groundbreaking technology companies. In his pivotal role, Greg is instrumental in identifying and supporting visionary founders who are building the next generation of industry-defining businesses. His investment thesis primarily centers on the convergence of healthcare, artificial intelligence, and enterprise software, areas where he brings profound expertise and a unique perspective.

Greg's investment focus within healthcare spans a wide spectrum, including biotech, digital health, and life sciences tools. He is particularly drawn to companies that leverage cutting-edge technology to solve complex problems in patient care, drug discovery, and medical research. His portfolio reflects a keen eye for innovation in areas like AI-driven drug development, precision medicine, and platforms that streamline scientific R&D. Beyond healthcare, Greg also actively invests in enterprise software solutions that enhance efficiency, drive digital transformation, and harness the power of AI for businesses across various sectors.

What truly sets Greg Yap apart is his exceptional career trajectory, which seamlessly blends deep medical knowledge with extensive technological acumen. He earned his Doctor of Medicine (MD) from Harvard Medical School and an MBA from Harvard Business School, providing him with a robust foundation in both clinical practice and business strategy. Prior to joining Menlo Ventures, Greg held significant product leadership positions at some of the world's most influential technology companies. At Google, he played a key role in product management for AI and machine learning initiatives within healthcare, gaining firsthand experience in applying advanced algorithms to real-world medical challenges. His tenure at Microsoft saw him leading product efforts in enterprise software, further solidifying his understanding of large-scale technology deployment and market needs. This diverse background, encompassing clinical insights, strategic business thinking, and hands-on tech development, empowers him to evaluate opportunities with a holistic and informed approach.

Greg's notable investments underscore his ability to spot transformative potential. His portfolio includes companies like Benchling, a leading life science R&D cloud platform; Recursion Pharmaceuticals, pioneering an AI-driven drug discovery platform; Synthego, a genome engineering company; Octave Bio, focused on precision neurology; and Pearl Health, an innovative value-based care platform. These investments exemplify his commitment to backing companies that are not only technologically advanced but also possess the potential for significant societal impact and market disruption. Through his strategic guidance and deep industry connections, Greg Yap continues to play a vital role in shaping the future of healthcare and enterprise technology at Menlo Ventures.